Superworth

Viatris price to book ratio VTRS

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026
1.4×
6-year median
0.7×
Against its 6-year history
99th
percentile: 0 is its lowest day, 100 its highest
6-year range
0.5× to 1.5×
Peer median
3.6×

Viatris' price to book ratio is 1.4× as of Oct 23, 2026.

That is above its 6-year median of 0.7×, higher than on 99% of days in the last 6 years.

Over that time it ranged from 0.5× in Apr 2025 to 1.5× in Oct 2026.

The median for 10 healthcare stocks of a similar size is 3.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.4×0.9×1.5×
20250.9×0.5×0.9×
20240.8×0.6×0.8×
20230.6×0.5×0.8×
20220.7×0.5×0.9×
20210.8×0.7×0.9×

Against its peers

Companies in Healthcare nearest Viatris' size, closest first, today.

CompanyPrice to book ratio
VTRSViatris1.4×
THCTenet Healthcare4.6×
STESTERIS3.1×
ZBHZimmer Biomet1.5×
MEDPMedpace43.1×
INCYIncyte3.7×
RVTYRevvity2.5×
UTHRUnited Therapeutics3.9×
LHLabcorp3.1×
DGXQuest Diagnostics3.6×
EXELExelixis8.7×
Peer median3.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Viatris

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.